Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.71 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.71 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.52 |
| ▸ | CHRNA5 | P30532 | 3/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30355559 | 1.00 | CYP11B1 (0.71) | CYP11B1CYP11B2CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL30355788 | 0.90 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL23524053 | 0.90 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL1119366 | 0.84 | CYP11B2 (1.00) | CYP11B1CYP11B2CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL30355386 | 0.80 | CYP11B1 (0.52) | CYP11B1CYP11B2CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL23523830 | 0.80 | CYP11B1 (0.52) | CYP11B1CYP11B2CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL23524034 | 0.76 | CYP11B1 (0.70) | CYP11B1CYP11B2CYP1A2CYP19A1NPC1 | |
| SCHEMBL30355642 | 0.76 | CYP11B1 (0.70) | CYP11B1CYP11B2CYP1A2CYP19A1NPC1 | |
| SCHEMBL16183810 | 0.75 | CYP11B1 (0.66) | CYP11B1CYP11B2CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL1422499 | 0.74 | NPC1 (0.58) | NPC1RAB9AS1PR1CHRNB2CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | CYP11B1 1869/4885CYP11B2 2298/4885CYP1A2 4278/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | CYP11B1 980/4885CYP11B2 1055/4885CYP1A2 2753/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | CYP11B1 1869/4885CYP11B2 2298/4885CYP1A2 4278/4885 |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | CYP11B1 1869/4885CYP11B2 2298/4885CYP1A2 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.